SHINIL PHARMACEUTICAL (012790) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, SHINIL PHARMACEUTICAL (012790) reported revenue of 80.6 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202580.6 billion KRW7.4 billion KRW7.5 billion KRW[source]
202489.4 billion KRW15.2 billion KRW14.3 billion KRW[source]
202389.1 billion KRW14.0 billion KRW13.6 billion KRW[source]
202280.0 billion KRW13.7 billion KRW12.2 billion KRW[source]
202161.8 billion KRW8.0 billion KRW6.7 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025169.5 billion KRW17.1 billion KRW152.3 billion KRW[source]
2024165.9 billion KRW19.4 billion KRW146.5 billion KRW[source]
2023152.5 billion KRW17.6 billion KRW134.9 billion KRW[source]
2022142.8 billion KRW19.6 billion KRW123.3 billion KRW[source]
2021129.0 billion KRW15.8 billion KRW113.2 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice